Dear all Just one minor comment from one of the not hard core users of NONMEM.
Only 3 years ago I was afraid that NONMEM would die, since no one really seemed to be interested in investing in the software. Today, in my eyes, NONMEM has been brought back on the scene by IDS - that is highly appreciated. I think we all have to realize that NONMEM is not open source software, there are both advantages and dis-advantages connected to that. As long as IDS ensures that we are able to make minor adjustments (like nsizes etc), I don't see a big problem. Right now I run the R software (+census and xpose), together with NONMEM, and find thats some of the best pices of open software I have seen. But I dont think the PKPD community is big enough for us to generate comparable software for PKPD modelling, and if we need professionel companies to develop our software, we will have to accept other terms. Instead I think we should focus on the positive side, NONMEM is alive, and if anyone wants to run an older version of NONMEM that's fine with me. But I will test version 7.0 - and I look forward to the release. Hope everyone will have a nice summer Br henrik _________________________________ Henrik Agersø Director, Head of Exploratory ADME, BRU Novo Nordisk A/S Novo Nordisk Park DK-2760 Måløv Denmark +45 4442 3522 (direct) +45 3079 3522 (mobile) [email protected] www.novonordisk.com<http://www.novonordisk.com/> Changing possibilities in haemophilia Our formulation remains the only recombinant treatment option for haemophilia patients with inhibitors. Learn more<http://www.novonordisk.com/about_us/improving_haemophilia/ChangingPossibilitiesActivities/HaemophiliaTreatment1.asp> This e-mail (including any attachments) is intended for the addressee(s) stated above only and may contain confidential information protected by law. You are hereby notified that any unauthorized reading, disclosure, copying or distribution of this e-mail or use of information contained herein is strictly prohibited and may violate rights to proprietary information. If you are not an intended recipient, please return this e-mail to the sender and delete it immediately hereafter. Thank you. ________________________________ From: [email protected] [mailto:[email protected]] On Behalf Of Eleveld, DJ Sent: 02 July 2009 23:32 To: Ludden, Thomas; [email protected] Cc: Krohn, Anthony Subject: RE: [NMusers] NONMEM 7 Update Dear all: There is no debate at all that investment in NONMEM should have a healthy return. I just dont understand how encryption is supposed to help. NONMEM 6 was not encrypted, what problems resulted from this? Did anything actually happen to the NONMEM 6 source code which must be avoided with NONMEM 7? The thinking "we must encrypt our souce code so nobody steals our IP" may be suitable for consumer goods where copyright violations are rampant and visibility is very low. But the small, highly specalized and very visible community of PK-PD analysis is a very different thing. My impression is that everyone takes thier NONMEM licences very seriously and I dont see any reason why this would change with NONMEM 7. There are usually upsides and downsides to these kinds of choices and a balance must be struck. I can think of a number of downsides to encryption but no real upsides. I was hoping to hear from others what the upside was. Just "protecting our IP" is, in my opinion, not a real reason becasue this does not actually generate any revenue. Douglas Eleveld -----Oorspronkelijk bericht----- Van: Ludden, Thomas [mailto:[email protected]] Verzonden: do 2-7-2009 15:15 Aan: Eleveld, DJ; [email protected] CC: Krohn, Anthony Onderwerp: RE: [NMusers] NONMEM 7 Update Dear All: Icon Development Solutions has invested in the further development of NONMEM. By mutual agreement with the University of California at San Francisco, NONMEM 7 is intellectual property belonging to IDS. However, IDS will continue to pay royalties to UCSF. The business plan under which NONMEM 7 was developed calls for the protection of the I.P. involved. In addition, NONMEM 7 contains several updated routines developed and owned by IMSL (Visual Numerics Inc.). Our agreement with IMSL stipulates that we will not distribute their source code. The installer will compile the software but will not allow the unencrypted source code to remain on the users computer. The licensing agreement will also stipulate that any attempt to access the source code will be a violation of the agreement. Some source code will be left unencrypted for various reasons, one being the need for users to change certain values in SIZES and perhaps other resource routines. Tom Thomas M. Ludden Ph.D. Vice-President, Pharmacometrics R&D ICON Development Solutions Tel: + 1 410 696 3040 Mob: + 1 410 258 2411 Fax: + 1 410 480 0776 Email: [email protected] Web: www.icondevsolutions.com <http://emailsignature/stationary/Icon_Development_Solutions.gif> ________________________________ From: Eleveld, DJ [mailto:[email protected]] Sent: Thursday, July 02, 2009 6:11 AM To: Ludden, Thomas; [email protected] Subject: RE: [NMusers] NONMEM 7 Update Can anyone explain what advantages encryted source code might have? For me at least, the NONMEM source code is already functionally encrypted because of my poor understanding of Fortran. But it is unclear to me what problem encryted source code actually solves. Can anyone enlighten me? Douglas Eleveld ________________________________ From: [email protected] on behalf of Ludden, Thomas Sent: Wed 01/07/2009 9:21 PM To: [email protected] Subject: [NMusers] NONMEM 7 Update Dear All: This is just a brief update regarding the availability of NONMEM 7. We had hoped to begin distribution of this new version at this time. However, there are some final code changes to be made followed by thorough testing. We hope to be able to begin distribution in early August. Please be certain that the contact information that we have on file for your license(s) is up to date. This is the person to whom NONMEM 7 will be sent . Please send any updates regarding the correct contact person to [email protected] <mailto:[email protected]> . Please note that NONMEM 7 will have a licensing system. More details will be provided as we approach the release date. Our experience with distributing binary code to the beta testers was very mixed. Some testers had no problems; others had considerable difficulty with achieving a successful installation. We are now considering the distribution of NONMEM 7, for the most part, as encrypted source code. An installation program will be included. The SIZES file and several other resource files will be left unencrypted so that the user can make desired changes prior to compilation as was possible with previous versions. This change in our method of distribution will require that a revised licensing agreement be executed. Regards, Bob Bauer Vice-President, Pharmacometrics Alison Boeckmann Consultant Bill Bachman Director, Pharmacometrics R&D Tom Ludden Vice-President, Pharmacometrics R&D ICON Development Solutions Tel: + 1 410 696 3040 Mob: + 1 410 258 2411 Fax: + 1 410 480 0776 Email: [email protected] Web: www.icondevsolutions.com ICON plc made the following annotations. ------------------------------------------------------------------------ ------ This e-mail transmission may contain confidential or legally privileged information that is intended only for the individual or entity named in the e-mail address. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or reliance upon the contents of this e-mail is strictly prohibited. If you have received this e-mail transmission in error, please reply to the sender, so that ICON plc can arrange for proper delivery, and then please delete the message. Thank You, ICON plc South County Business Park Leopardstown Dublin 18 Ireland Registered number: 145835 ________________________________ De inhoud van dit bericht is vertrouwelijk en alleen bestemd voor de geadresseerde(n). Anderen dan de geadresseerde(n) mogen geen gebruik maken van dit bericht, het niet openbaar maken of op enige wijze verspreiden of vermenigvuldigen. Het UMCG kan niet aansprakelijk gesteld worden voor een incomplete aankomst of vertraging van dit verzonden bericht. The contents of this message are confidential and only intended for the eyes of the addressee(s). Others than the addressee(s) are not allowed to use this message, to make it public or to distribute or multiply this message in any way. The UMCG cannot be held responsible for incomplete reception or delay of this transferred message. ICON plc made the following annotations. ------------------------------------------------------------------------------ This e-mail transmission may contain confidential or legally privileged information that is intended only for the individual or entity named in the e-mail address. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or reliance upon the contents of this e-mail is strictly prohibited. If you have received this e-mail transmission in error, please reply to the sender, so that ICON plc can arrange for proper delivery, and then please delete the message. Thank You, ICON plc South County Business Park Leopardstown Dublin 18 Ireland Registered number: 145835 ________________________________ De inhoud van dit bericht is vertrouwelijk en alleen bestemd voor de geadresseerde(n). Anderen dan de geadresseerde(n) mogen geen gebruik maken van dit bericht, het niet openbaar maken of op enige wijze verspreiden of vermenigvuldigen. Het UMCG kan niet aansprakelijk gesteld worden voor een incomplete aankomst of vertraging van dit verzonden bericht. The contents of this message are confidential and only intended for the eyes of the addressee(s). Others than the addressee(s) are not allowed to use this message, to make it public or to distribute or multiply this message in any way. The UMCG cannot be held responsible for incomplete reception or delay of this transferred message.
